



October 6, 2025

The Honorable Robert F. Kennedy Jr.  
Secretary  
Department of Health and Human Services  
200 Independence Avenue SW  
Washington, D.C. 20201

Dear Secretary Kennedy,

The American Center for Law and Justice (ACLJ) commends you for your recent announcement initiating a formal investigation into the safety of mifepristone, a chemical abortion drug responsible for over 60% of abortions nationwide. Your willingness to fully examine the health risks posed by this drug is a necessary and courageous step—one that places human dignity and medical integrity above political pressure.

In light of that announced review, we were deeply troubled to learn that on September 30 the Food and Drug Administration (FDA) approved a new generic version of mifepristone. This decision is not only in contravention of the pro-life posture of the Trump Administration, but it also comes before your investigation has concluded, effectively expanding access to a drug whose safety remains in serious question.

Research continues to show that mifepristone poses a range of serious medical risks to women including hemorrhage, infection, and even death. Yet, rather than pause until completing a full and transparent review, the FDA moved forward with a new drug approval that may have life-altering health consequences for countless women while also ending the lives of their unborn children.

This moment demands an immediate and thorough review of the drug's adverse effects and regulatory history. Therefore, we respectfully urge you to prioritize and expedite this investigation into mifepristone.

Your leadership in pursuing this investigation is a welcome sign that federal health policy will reflect both scientific rigor and the sanctity of life. As an organization dedicated to defending the right to life and restoring accountability in our public institutions, the ACLJ stands ready to support your efforts.

Sincerely,

Jordan Sekulow  
Executive Director

★